I'm thinking that because the treatment is only 3 weeks in duration that it is not likely to be long before we hear anything.

I am also getting excited to find out if the higher dose arm provided a measurable benefit over the lower dose.

Lastly, this study is specific to platinum resistant ovarian cancer, so if Kevetrin helps you can bet that the whole world will catch wind of this. They set up the trial with a high bar because Dr. Mennon has confidence in Kevetrin and they know that if successful, suitors will becoming left and right and docs will use it off label for other tumors.